The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025GBA1 Consortium: Joint Analysis to Inform Clinical Trials
Study Rationale: Variants in the GB1A gene represent the most important genetic risk factor for Parkinson’s disease (PD) across the globe. However, different GBA1 variants are associated with varied...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Development of Alpha-synuclein Seed Amplification Assay in Cerebrospinal Fluid as a Robust Biomarker of Synucleinopathies
Study Rationale: Progressive aggregation of alpha-synuclein and the subsequent loss of affected brain cells starts 10 to 20 years before the onset of Parkinson’s disease (PD) symptoms. Early diagnosis...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2024Investigating the Early Events in Parkinson’s Disease Pathobiology through Longitudinal Evaluation of Asymptomatic Carriers of Alpha-synuclein Mutations
Study Rationale: Essentially nothing is known about the sequence of biological and physiological events that ultimately lead to the clinical manifestations of Parkinson’s disease (PD). The existence...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Characterization of a Preclinical Model Bearing a Parkinson’s Disease–linked Mutation in PLA2G6
Study Rationale: Mutations in the PLA2G6 gene lead to neurodegeneration linked to Parkinson’s disease (PD), but the mechanism is unknown. The gene encodes an enzyme that breaks down the lipid...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Targeting Mitochondrial Complex I in Parkinson’s Disease
Study Rationale: Three of the primary risk factors for Parkinson's disease (PD)—aging, environmental toxins and genetic mutations—all lead to impaired function of mitochondria, structures that...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Evaluating the Role of CK1d Inhibition in Sleep Dysregulation and Alpha-synuclein Pathology in Preclinical Models of Parkinson’s Disease
Study Rationale: Disrupted sleep is an early sign of Parkinson’s disease (PD) that worsens as the disease progresses. Chronic symptoms of PD include alternations in sleep patterns and changes in the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.